- 癌症检测公司拓展全球市场-

美国商业资讯2006年11月15日凤凰城消息－－

Zila, Inc. （纳斯达克GM股票代码：ZILA）今天宣布公司已从一家台湾公司President Medical Technologies, Inc.手中获得在泛太平洋地区生产和销售ViziLite(R)的权利。这一交易使Zila从ViziLite技术的被许可人成为ViziLite的所有权人之一，这些权利包括包括基础专利技术以及全球销售。

Zila正在执行其将ViziLite Plus构建为口腔癌症检测新标准的计划。ViziLite Plus是市面上用于可能导致癌症的口腔异常情况早期检测最为先进的技术。Zila的下一代口腔癌症诊断产品，OraTest，目前正在进行三期临床试验。

Zila主席、首席执行官兼总裁Douglas Burkett博士说：“口腔癌症在泛太平洋地区是流行性致命疾病。本次交易为我们的癌症检测产品在泛太平洋地区销售寻找战略性合作伙伴铺平了道路。我们的目标不仅仅是在美国的口腔医院，而是最终在全球范围内把ViziLite Plus树立成为保健标准。”

在昨天的另一新闻发布会上， Zila宣布计划收购Professional Dental Technologies ("Pro-Dentec(R)") 来增强公司在美国区域营销其口腔癌症检测产品的能力。

关于口腔癌症

口腔癌症是全球范围内最为致命的癌症种类之一，居高死亡率很大程度上是由于约有三分之二的口腔癌症患者直到晚期才被发现。如果能在早期检测出口腔癌症，病人的存活率在80%左右；而如果在晚期才被检测出，存活率则会降低到20%。美国牙科协会表示虽然大部分的口腔癌症患者是由于吸烟以及/或者饮酒过度而导致，但还有超过四分之一的患者从不吸烟，也没有其他不良嗜好。

关于Zila, Inc.

Zila, Inc.总部位于凤凰城，是一家最初专注口腔癌症的领先癌症检测公司：

-- Zila Pharmaceuticals致力于将ViziLite(R) Plus构建成为可能导致癌症的口腔异常状况早期检测新标准。

-- Zila Biotechnology致力于为下一代口腔癌症诊断产品OraTest(R)获得药品注册审批，同时进行癌症检测技术的其他应用开发，包括颈部和食管癌症早期检测产品。

有关Zila的更多信息，请访问 www.zila.com 。

此新闻稿含有《1933年证券管理条例》第27节第一条和《1934年证券交易税案》第21节第5条所规定的“前瞻性声明”。这些前瞻性声明很大程度上取决去Zila的预期或者未来事件的预测，会受到不准确假设、各种商业风险和已知、未知不确定因素的影响，其中大部分因素公司无法控制。因此，真实结果可能与本新闻稿中的前瞻性声明大相径庭。很多因素都可能导致这些差异，并将严重损害公司的收入、盈利状况、现金流和资本需要。我们无法保证本新闻稿中所包含的前瞻性声明将成为现实。有关可能影响Zila未来业绩的风险因素的更多详细描述，请参考Zila提交的2006年7月31日结束财年10-K表格。

联系方式：Zila, Inc. Andrew Stevens, 602-266-6700 或者 投资者关系部门 投资者关系 Antima "Taz" Sadhukhan/Dian Griesel, 212-825-3210 或者 媒体： Bill Douglass, 212-825-3210

(BW)(AZ-ZILA)(ZILA) Zila, Inc. Adds Pacific Rim To ViziLite Market

- Cancer Detection Company Extends Global Reach -

PHOENIX--(BUSINESS WIRE)--Nov. 15, 2006--

Zila, Inc. (Nasdaq GM: ZILA) reported today that it has acquired the rights to manufacture and distribute ViziLite(R) in the Pacific Rim from President Medical Technologies, Inc., a Taiwanese company. This transaction completes the evolution of Zila from a licensee of the ViziLite technology to one of sole owner of all ViziLite rights, including the underlying patented technology and world-wide distribution.

Zila is executing its plan to establish ViziLite Plus as the new standard of care in oral cancer detection. ViziLite Plus is the most advanced technology on the market for the early detection of oral abnormalities that could lead to cancer. Zila's next generation oral cancer diagnostic product, OraTest, is currently proceeding through a Phase III clinical trial.

"Oral cancer is a prevalent and deadly disease within the Pacific Rim. This transaction paves the way for strategic alliances for the distribution of our cancer detection products within the Pacific Rim. It is our goal to establish ViziLite Plus as the standard of care, not only in dental offices across the United States, but ultimately around the world," stated Zila Chairman, CEO and President, Douglas Burkett, Ph.D.

In a separate release yesterday, Zila announced its plan to acquire Professional Dental Technologies ("Pro-Dentec(R)") in order to strengthen the Company's ability to market and sell its oral cancer detection products in the United States.

About Oral Cancer

Oral cancer is among the most deadly cancer types globally, largely owing to the fact that roughly two-thirds of all oral cancers are detected at advanced stage. When oral cancer is detected early, survival rates are about 80%; detected late, the survival rate falls to 20%. The American Dental Association says that while most cases of oral cancer affect people who use tobacco and/or drink heavily, more than a quarter of oral cancers occur in people who do not smoke and have no other risk factors.

About Zila, Inc.

Zila, Inc., headquartered in Phoenix, is a leading cancer diagnostic company initially focused on oral cancer:

-- Zila Pharmaceuticals is dedicated to establishing ViziLite(R) Plus as the new standard of care for the early detection of oral abnormalities that could lead to cancer.

-- Zila Biotechnology is focused on achieving regulatory approval for the next generation oral cancer diagnostic, OraTest(R), followed by the development of additional applications of its cancer detection technologies including products for the early detection of cervical and esophageal cancer.

For more information about Zila, visit www.zila.com .

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31,2006.

CONTACT: Zila, Inc. Andrew Stevens, 602-266-6700 or The Investor Relations Group Investor Relations: Antima "Taz" Sadhukhan/Dian Griesel, 212-825-3210 or Media: Bill Douglass, 212-825-3210